The Food and Drug Administration's oncologic drugs advisory committee on voted against approval of GSK's blood cancer drug Blenrep. The British pharmaceutical company said Thursday combinations for ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

Antibody-Drug Conjugates (ADC) Market- Driven by Advanced Payload Technologies and Strategic Industry Partnerships Sai Kumar DataM Intelligence 4market Research LLP +1 877-441-4866 ... Visit us on ...

Planning your first trip to Japan? These essential travel tips cover everything from etiquette to apps—what to know before you go in 2025.

The NICE guidance recommends belantamab mafodotin (brand name Blenrep, made by GlaxoSmithKline) with bortezomib and dexamethasone as an option for some adults with multiple myeloma at a specific stage ...

WASHINGTON, June 20 (Reuters) - Japan has canceled an annual high-level meeting with key ally the United States after the Trump administration demanded it spend more on defense, the Financial ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.